ibrunat 140mg

Ibrunat 140mg is a prescription medication used to treat certain types of cancer, including B-cell lymphoma, chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). It is a Bruton’s tyrosine kinase (BTK) inhibitor that works by inhibiting the growth of cancer cells and reducing the production of new blood vessels that feed the tumor.

Composition:

• Ibrunat 140mg: Ibrutinib 140mg

Mechanism of Action:

Ibrutinib, the active ingredient in Ibrunat, is a BTK inhibitor that works by:

1. Inhibiting the growth of cancer cells by blocking the action of BTK, a protein that is involved in the survival and proliferation of cancer cells.
2. Reducing the production of new blood vessels that feed the tumor, which helps to reduce its growth and spread.
3. Inhibiting the activity of various signaling pathways that contribute to cancer cell growth and survival.

Indications:

Ibrunat is approved for the treatment of:

1. Relapsed or refractory mantle cell lymphoma (MCL) in patients who have not responded to other treatments.
2. Relapsed or refractory chronic lymphocytic leukemia (CLL) in patients who have not responded to other treatments.
3. Waldenström macroglobulinemia (WM) in patients who have not responded to other treatments.

Dosage:

The recommended dosage of Ibrunat is:

• 140mg orally once daily, taken at the same time every day.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Ibrunat include:

1. Fatigue
2. Nausea
3. Vomiting
4. Diarrhea
5. Abdominal pain
6. Constipation
7. Increased risk of bleeding or bruising
8. Skin rash
9. Hair loss
10. Muscle pain

Recommendation:

Ibrunat is recommended for patients who have been diagnosed with B-cell lymphoma, CLL, or MCL and have not responded to other treatments or have disease that has progressed after surgery and radiation therapy.

Important Note:

• Patients taking Ibrunat should be closely monitored for signs of bleeding or bruising due to the risk of thrombocytopenia.
• Patients taking Ibrunat should avoid taking medications that may increase the risk of bleeding or bruising.
• Pregnant or breastfeeding women should not use Ibrunat, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Ibrunat and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of kidney disease should be closely monitored for signs of worsening kidney function while taking Ibrunat.
• Patients taking Ibrunat should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase blood pressure.
• Patients with a history of heart disease or high blood pressure should be closely monitored while taking Ibrunat.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Ibrunat.
• Patients who are allergic to ibrutinib or any other component of Ibrunat should not use it.
• Patients who are pregnant or breastfeeding should not use Ibrunat.